Sailan Pharmaceutical Technology

CytosinLab, formerly Sailan Pharmaceutical Technology, is a Chinese clinical-stage biotechnology company focused on epigenetics-based oncology drug discovery and development. The company develops small-molecule therapeutics aimed at novel cancer biology targets and has built an internal epigenetics platform, EpigenPLUS, to identify and advance first-in-class programs. Its disclosed pipeline includes CTS2016, an oral AXL/FLT3 inhibitor in Phase 1 for hematologic malignancies and potentially solid tumors, as well as additional preclinical epigenetic programs targeting thymine DNA glycosylase and PRMT5-MTA biology. CytosinLab has raised venture financing, joined the Roche Accelerator ecosystem in China, and operates from Hangzhou with R&D activities in Hangzhou and Shanghai.